StockData
APTNOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ADAPTIN BIO, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$6.27+0.00 (0.00%)

Close on Aug 19, 2026

Market cap
$55.48M
P/E (TTM)
–
Dividend yield
–

SEC filings

19 of Adaptin Bio's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KAug 20, 2026Aug 25, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 13, 2026SEC EDGAR
Annual report, amended10-K/ADec 31, 2025Jun 12, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 15, 2026SEC EDGAR
Current report8-KApr 6, 2026Apr 6, 2026SEC EDGAR
Annual report10-KDec 31, 2025Apr 1, 2026SEC EDGAR
Current report8-KDec 22, 2025Dec 23, 2025SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 14, 2025SEC EDGAR
Current report8-KOct 3, 2025Oct 6, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 14, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 15, 2025SEC EDGAR
Annual report10-KDec 31, 2024Apr 15, 2025SEC EDGAR
Current report8-KApr 7, 2025Apr 9, 2025SEC EDGAR
Current report8-KFeb 11, 2025Feb 18, 2025SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 14, 2024SEC EDGAR
Quarterly report10-QJun 30, 2024Aug 14, 2024SEC EDGAR
Quarterly report10-QMar 31, 2024May 15, 2024SEC EDGAR
Annual report10-KDec 31, 2023Apr 1, 2024SEC EDGAR
Quarterly report10-QSep 30, 2023Nov 14, 2023SEC EDGAR